Fairmount Funds Management LLC
- SEC CIK
- 0001802528
- Latest filing
- Aug 14, 2026
Holdings in Q4 2024
Holdings as of Dec 31, 2024, filed Feb 14, 2025. Long positions only; changes compare share counts with Q3 2024.
- Positions
- 17
- +2 vs. Q3 2024
- Portfolio value
- $1.01B
- −$227.4M (−18.4%) vs. Q3 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| AXSMAxsome Therapeutics, Inc. | COM | 1,468,983 | $124.3M | 12.4% | −891,094−37.8% | Reduced | History |
| NUVLNuvalent, Inc. | COM | 1,317,664 | $103.1M | 10.3% | −369,400−21.9% | Reduced | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 4,018,101 | $93.5M | 9.3% | 00.0% | Unchanged | History |
| APGEApogee Therapeutics, Inc. | COM | 2,048,647 | $92.8M | 9.2% | 00.0% | Unchanged | History |
| SRRKScholar Rock Holding Corp | COM | 1,962,953 | $84.8M | 8.4% | +1,962,953 | New | History |
| ELVNEnliven Therapeutics, Inc. | COM | 3,202,798 | $72.1M | 7.2% | 00.0% | Unchanged | History |
| VRDNViridian Therapeutics, Inc. | COM | 3,445,813 | $66.1M | 6.6% | 00.0% | Unchanged | History |
| ORKAOruka Therapeutics, Inc. | COM | 3,371,922 | $65.4M | 6.5% | +160,000+5.0% | Added | History |
| DNTHDianthus Therapeutics, Inc. | COM | 2,700,691 | $58.9M | 5.9% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 6,225,641 | $48.6M | 4.8% | 00.0% | Unchanged | History |
| KNSAKiniksa Pharmaceuticals International, plc | ORD SHS CL A | 2,194,341 | $43.4M | 4.3% | −1,010,500−31.5% | Reduced | History |
| DAWNDay One Biopharmaceuticals, Inc. | Stock | 3,103,448 | $39.3M | 3.9% | 00.0% | Unchanged | History |
| ATXSAstria Therapeutics, Inc. | COM | 3,554,129 | $31.8M | 3.2% | 00.0% | Unchanged | History |
| ANABAnaptysbio, Inc | COM | 1,816,466 | $24.1M | 2.4% | +1,816,466 | New | History |
| BCAXBicara Therapeutics Inc. | COM | 1,284,169 | $22.4M | 2.2% | 00.0% | Unchanged | History |
| IKTInhibikase Therapeutics, Inc. | COM NEW | 6,125,000 | $19.9M | 2.0% | +6,125,000 | New | History |
| ZBIOZenas BioPharma, Inc. | COM | 1,892,806 | $15.5M | 1.5% | 00.0% | Unchanged | History |
Sold out since Q3 2024 (1)
Positions held at the end of Q3 2024 that are gone from this filing.